Posts for the 'Trasylol' Category
Trasylol recall issued
Although Bayer AG agreed to stop marketing their heart surgery injection Trasylol in November 2007, they are now removing any remaining stock of the drug from the U.S. market following a study published in the New England Journal of Medicine. The Trasylol recall was issued after data from a Canadian study confirmed that those treated with the injection faced a substantial increased risk of death.
>>INFORMATION: Trasylol Recall Lawsuits
Studies show additional evidence of Trasylol heart surgery injection problems
Evidence continues to confirm that the heart surgery injection Trasylol greatly increases the risk of kidney complications and death. A Trasylol recall was issued last November following nearly two years of concerns about the drug’s link with reports of kidney damage and death. A recent report on CBS’s 60 Minutes indicated that as many as 22,000 deaths could have been caused by the injection.
>>INFORMATION: Trasylol Heart Surgery Injection Problems
CBS 60 Minutes Report: Trasylol Injection linked to 22,000 Deaths
According to a report which will be broadcast Sunday on CBS Television’s 60 Minutes, 22,000 deaths could have been prevented if Bayer and the FDA had issued a Trasylol recall earlier. Although a study was presented in January 2006 which demonstrated a link between Trasylol and serious side effects, the heart surgery injection was not removed from the market until November 2007. The lawyers at Saiontz & Kirk, P.A. are reviewing potential Trasylol lawsuits on behalf of individuals who suffered kidney failure, a heart attack, stroke or death after receiving an injection before open heart surgery.
>>INFORMATION: Trasylol Injection Lawsuits
Trasylol side effects blamed for over 200 deaths
According to a recent report from the New York Post, at least 235 deaths could be blamed on Trasylol side effects. The heart surgery drug given to control bleeding has been linked to problems such as an increased risk of kidney damage, congestive heart failure, heart attacks and strokes.
>>INFORMATION: Trasylol Side Effects
FDA requested Bayer stop sales of Trasylol injection
The FDA announced today that they requested Bayer Pharmaceuticals halt further sales of Trasylol pending their review of data from a Canadian study which suggests that the heart surgery injection significantly increases the risk of death. The injection has been under scrutiny from regulators for nearly two years as a result of findings that it increases the risk of serious and potentially fatal injuries. The lawyers at Saiontz & Kirk, P.A. have been investigating potential Trasylol lawsuits since February 2006, and are continuing to review new claims.
>>INFORMATION: FDA Trasylol Notice
FDA to review increased Trasylol death risk after study halted
The FDA announced this week that they will take another look at the overall risks and benefits of Trasylol, a heart surgery injection used to control bleeding. Trasylol has been previously linked to an increased risk of serious and potentially fatal injuries, such as kidney failure, heart attacks and strokes. Recently a Canadian study was stopped after evidence clearly suggested that Trasylol increases the risk of death when compared with other drugs.
>>INFORMATION: Trasylol Lawsuits
FDA panel does not recommend Trasylol recall
An FDA advisory panel met last week and found that a Trasylol recall is not warranted at this time, despite evidence that suggests the drug may increase the risk of kidney failure, heart failure, stroke and death. The recommendation was made after the panel of experts had an opportunity to review additional data which the manufacturer, Bayer AG, failed to provide to the FDA before a prior hearing in September 2006.
>>PRIOR POST (9/11/2006): Heart surgery injection increases risk of
kidney failure and death
Heart bypass surgery injection increases risk of kidney failure and death
According to FDA staff members, a heart bypass surgery injection known as Trasylol (aprotonin), appears to increase the risk of kidney failure, heart attacks, strokes and death. The statement was yesterday in advance of an advisory panel meeting scheduled to begin tomorrow.
>>INFORMATION: Heart Bypass Surgery Injection Problems
FDA to review safety of Trasylol for a second time
The FDA will hold a second advisory panel meeting on September 12, 2007 to review the safety of Bayer AG’s heart surgery aprotonin injection, marketed as Trasylol. Following a prior meeting of experts in September 2006, regulators decided against a Trasylol recall and instead decided to require stronger warnings for the injection and limit its use to certain situations. However, it was discovered after these hearings that Bayer employees withheld information about studies which demonstrated the deadly side effects of the injection. Read the rest of this entry »
Trasylol heart surgery injection problems
Trasylol (also known as aprotinin) is a heart bypass surgery injection which is given to reduce blood loss during the procedure. Last year the aprotinin injection was linked to an increased risk of kidney failure, heart attacks and strokes. A recent study adds to the concerns surrounding the injection, finding that it may increase the risk of death by 50% over the five years after the heart bypass surgery. Read the rest of this entry »
